# Fuelcell Energy Inc: financial statements, quarterly

FCEL · Nasdaq · CIK 886128 · [Technology](/sectors/technology.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/fcel.md) · [Financials](/companies/fcel/financials.md) · [Filings](/companies/fcel/filings.md) · [Insiders](/companies/fcel/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fcel/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.5 d](/filings/0001104659-25-122302.md) | [16.7](/filings/0001558370-25-002637.md) | [22.4](/filings/0001558370-25-008463.md) | [23.7](/filings/0001558370-25-011952.md) | [49.3 d](/filings/0001104659-25-122302.md) | [19.0](/filings/0001104659-26-024970.md) | [37.4](/filings/0001104659-26-071183.md) | [46.7](/filings/0001104659-26-104501.md) | [55.0 d](/filings/0001104659-25-122302.md) | [30.5](/filings/0001104659-26-024970.md) | [35.6](/filings/0001104659-26-071183.md) | [33.0](/filings/0001104659-26-104501.md) |
| Cost of revenue | $m | [23.9 d](/filings/0001104659-25-122302.md) | [28.4](/filings/0001558370-25-002637.md) | [29.5](/filings/0001558370-25-008463.md) | [29.9](/filings/0001558370-25-011952.md) | [60.2 d](/filings/0001104659-25-122302.md) | [24.2](/filings/0001104659-26-024970.md) | [46.8](/filings/0001104659-26-071183.md) | [51.9](/filings/0001104659-26-104501.md) | [61.6 d](/filings/0001104659-25-122302.md) | [36.4](/filings/0001104659-26-024970.md) | [48.5](/filings/0001104659-26-071183.md) | [57.5](/filings/0001104659-26-104501.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [18.0 d](/filings/0001104659-25-122302.md) | [14.4](/filings/0001558370-25-002637.md) | [16.6](/filings/0001558370-25-008463.md) | [12.8](/filings/0001558370-25-011952.md) | [11.6 d](/filings/0001104659-25-122302.md) | [11.1](/filings/0001104659-26-024970.md) | [9.9](/filings/0001104659-26-071183.md) | [7.6](/filings/0001104659-26-104501.md) | [5.5 d](/filings/0001104659-25-122302.md) | [7.0](/filings/0001104659-26-024970.md) | [7.7](/filings/0001104659-26-071183.md) | [8.5](/filings/0001104659-26-104501.md) |
| Selling, general and administrative | $m | [16.9 d](/filings/0001104659-25-122302.md) | [16.4](/filings/0001558370-25-002637.md) | [17.7](/filings/0001558370-25-008463.md) | [14.6](/filings/0001558370-25-011952.md) | [15.9 d](/filings/0001104659-25-122302.md) | [15.0](/filings/0001104659-26-024970.md) | [16.5](/filings/0001104659-26-071183.md) | [14.1](/filings/0001104659-26-104501.md) | [15.2 d](/filings/0001104659-25-122302.md) | [13.5](/filings/0001104659-26-024970.md) | [14.7](/filings/0001104659-26-071183.md) | [13.6](/filings/0001104659-26-104501.md) |
| Operating income | $m | [(36.4) d](/filings/0001104659-25-122302.md) | [(42.5)](/filings/0001558370-25-002637.md) | [(41.4)](/filings/0001558370-25-008463.md) | [(33.6)](/filings/0001558370-25-011952.md) | [(41.0) d](/filings/0001104659-25-122302.md) | [(32.9)](/filings/0001104659-26-024970.md) | [(35.8)](/filings/0001104659-26-071183.md) | [(95.4)](/filings/0001104659-26-104501.md) | [(28.3) d](/filings/0001104659-25-122302.md) | [(26.3)](/filings/0001104659-26-024970.md) | [(77.9)](/filings/0001104659-26-071183.md) | [(46.7)](/filings/0001104659-26-104501.md) |
| Interest expense | $m | [2.3 d](/filings/0001104659-25-122302.md) | [2.3](/filings/0001558370-25-002637.md) | [2.3](/filings/0001558370-25-008463.md) | [2.6](/filings/0001558370-25-011952.md) | [2.5 d](/filings/0001104659-25-122302.md) | [2.6](/filings/0001104659-26-024970.md) | [2.5](/filings/0001104659-26-071183.md) | [2.5](/filings/0001104659-26-104501.md) | [2.7 d](/filings/0001104659-25-122302.md) | [2.8](/filings/0001104659-26-024970.md) | [2.9](/filings/0001104659-26-071183.md) | [2.9](/filings/0001104659-26-104501.md) |
| Income tax | $m | [0.0 d](/filings/0001104659-25-122302.md) | not reported | not reported | [0.0](/filings/0001558370-25-011952.md) | [0.0 d](/filings/0001104659-25-122302.md) | not reported | [0.1](/filings/0001104659-26-071183.md) | [0.0](/filings/0001104659-26-104501.md) | [0.0 d](/filings/0001104659-25-122302.md) | not reported | [(0.1)](/filings/0001104659-26-071183.md) | [0.0 d](/filings/0001104659-26-104501.md) |
| Net income | $m | [(30.4) d](/filings/0001104659-25-122302.md) | [(19.8)](/filings/0001558370-25-002637.md) | [(32.1)](/filings/0001558370-25-008463.md) | [(32.7)](/filings/0001558370-25-011952.md) | [(41.4) d](/filings/0001104659-25-122302.md) | [(28.3)](/filings/0001104659-26-024970.md) | [(38.0)](/filings/0001104659-26-071183.md) | [(91.7)](/filings/0001104659-26-104501.md) | [(29.9) d](/filings/0001104659-25-122302.md) | [(22.9)](/filings/0001104659-26-024970.md) | [(77.9)](/filings/0001104659-26-071183.md) | [(44.5)](/filings/0001104659-26-104501.md) |
| Diluted EPS | $ per share | not reported | [(1.37)](/filings/0001558370-25-002637.md) | [(2.18)](/filings/0001558370-25-008463.md) | [(1.99)](/filings/0001558370-25-011952.md) | not reported | [(1.42)](/filings/0001104659-26-024970.md) | [(1.79)](/filings/0001104659-26-071183.md) | [(3.78)](/filings/0001104659-26-104501.md) | not reported | [(0.49)](/filings/0001104659-26-024970.md) | [(1.45)](/filings/0001104659-26-071183.md) | [(0.64)](/filings/0001104659-26-104501.md) |
| Basic EPS | $ per share | not reported | [(1.37)](/filings/0001558370-25-002637.md) | [(2.18)](/filings/0001558370-25-008463.md) | [(1.99)](/filings/0001558370-25-011952.md) | not reported | [(1.42)](/filings/0001104659-26-024970.md) | [(1.79)](/filings/0001104659-26-071183.md) | [(3.78)](/filings/0001104659-26-104501.md) | not reported | [(0.49)](/filings/0001104659-26-024970.md) | [(1.45)](/filings/0001104659-26-071183.md) | [(0.64)](/filings/0001104659-26-104501.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [250](/filings/0001104659-25-122302.md) | [297](/filings/0001558370-25-002637.md) | [159](/filings/0001558370-25-008463.md) | [159](/filings/0001558370-25-011952.md) | [148](/filings/0001104659-25-122302.md) | [98.1](/filings/0001104659-26-024970.md) | [116](/filings/0001104659-26-071183.md) | [175](/filings/0001104659-26-104501.md) | [278](/filings/0001104659-26-104501.md) | [312](/filings/0001104659-26-024970.md) | [373](/filings/0001104659-26-071183.md) | [658](/filings/0001104659-26-104501.md) |
| Current assets | $m | [476](/filings/0001558370-24-016497.md) | [445](/filings/0001558370-24-002673.md) | [426](/filings/0001558370-24-009026.md) | [460](/filings/0001558370-24-012598.md) | [444](/filings/0001104659-25-122302.md) | [411](/filings/0001558370-25-002637.md) | [384](/filings/0001558370-25-008463.md) | [370](/filings/0001558370-25-011952.md) | [450](/filings/0001104659-26-104501.md) | [495](/filings/0001104659-26-024970.md) | [544](/filings/0001104659-26-071183.md) | [833](/filings/0001104659-26-104501.md) |
| Total assets | $m | [956](/filings/0001558370-24-016497.md) | [923](/filings/0001558370-24-002673.md) | [917](/filings/0001558370-24-009026.md) | [949](/filings/0001558370-24-012598.md) | [944](/filings/0001104659-25-122302.md) | [908](/filings/0001558370-25-002637.md) | [884](/filings/0001558370-25-008463.md) | [831](/filings/0001558370-25-011952.md) | [932](/filings/0001104659-26-104501.md) | [978](/filings/0001104659-26-024970.md) | [1,003](/filings/0001104659-26-071183.md) | [1,311](/filings/0001104659-26-104501.md) |
| Current liabilities | $m | [65.9](/filings/0001558370-24-016497.md) | [53.9](/filings/0001558370-24-002673.md) | [65.0](/filings/0001558370-24-009026.md) | [66.5](/filings/0001558370-24-012598.md) | [73.9](/filings/0001104659-25-122302.md) | [64.9](/filings/0001558370-25-002637.md) | [68.4](/filings/0001558370-25-008463.md) | [69.0](/filings/0001558370-25-011952.md) | [67.8](/filings/0001104659-26-104501.md) | [62.1](/filings/0001104659-26-024970.md) | [63.3](/filings/0001104659-26-071183.md) | [96.1](/filings/0001104659-26-104501.md) |
| Total liabilities | $m | [195](/filings/0001558370-24-016497.md) | [181](/filings/0001558370-24-002673.md) | [205](/filings/0001558370-24-009026.md) | [204](/filings/0001558370-24-012598.md) | [217](/filings/0001104659-25-122302.md) | [202](/filings/0001558370-25-002637.md) | [205](/filings/0001558370-25-008463.md) | [205](/filings/0001558370-25-011952.md) | [201](/filings/0001104659-26-104501.md) | [214](/filings/0001104659-26-024970.md) | [215](/filings/0001104659-26-071183.md) | [268](/filings/0001104659-26-104501.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [10.1](/filings/0001558370-24-016497.md) | [10.2](/filings/0001558370-24-002673.md) | [11.7](/filings/0001558370-24-009026.md) | [12.2](/filings/0001558370-24-012598.md) | [15.9](/filings/0001104659-25-122302.md) | [16.9](/filings/0001558370-25-002637.md) | [17.1](/filings/0001558370-25-008463.md) | [16.7](/filings/0001558370-25-011952.md) | [15.8](/filings/0001104659-26-104501.md) | [17.8](/filings/0001104659-26-024970.md) | [17.4](/filings/0001104659-26-071183.md) | [18.8](/filings/0001104659-26-104501.md) |
| Shareholders' equity | $m | [682](/filings/0001558370-24-016497.md) | [664](/filings/0001558370-24-002673.md) | [640](/filings/0001558370-24-009026.md) | [676](/filings/0001558370-24-012598.md) | [657](/filings/0001104659-25-122302.md) | [635](/filings/0001558370-25-002637.md) | [609](/filings/0001558370-25-008463.md) | [556](/filings/0001558370-25-011952.md) | [662](/filings/0001104659-26-104501.md) | [695](/filings/0001104659-26-024970.md) | [719](/filings/0001104659-26-071183.md) | [975](/filings/0001104659-26-104501.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.8) d](/filings/0001104659-25-122302.md) | [(58.3)](/filings/0001558370-25-002637.md) | [(37.1) d](/filings/0001558370-25-008463.md) | [(63.4) d](/filings/0001558370-25-011952.md) | [5.8 d](/filings/0001104659-25-122302.md) | [(45.7)](/filings/0001104659-26-024970.md) | [(29.9) d](/filings/0001104659-26-071183.md) | [(26.8) d](/filings/0001104659-26-104501.md) | [(22.9) d](/filings/0001104659-25-122302.md) | [(33.9)](/filings/0001104659-26-024970.md) | [(27.3) d](/filings/0001104659-26-071183.md) | [(12.2) d](/filings/0001104659-26-104501.md) |
| Capital expenditure | $m | [11.3 d](/filings/0001104659-25-122302.md) | [10.6](/filings/0001558370-25-002637.md) | [13.2 d](/filings/0001558370-25-008463.md) | [13.4 d](/filings/0001558370-25-011952.md) | [10.5 d](/filings/0001104659-25-122302.md) | [7.1](/filings/0001104659-26-024970.md) | [5.3 d](/filings/0001104659-26-071183.md) | [5.2 d](/filings/0001104659-26-104501.md) | [1.0 d](/filings/0001104659-25-122302.md) | [0.8](/filings/0001104659-26-024970.md) | [1.7 d](/filings/0001104659-26-071183.md) | [1.3 d](/filings/0001104659-26-104501.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [406](/filings/0001558370-24-002673.md) | [406](/filings/0001558370-24-009026.md) | [416](/filings/0001558370-24-012598.md) | [15.1](/filings/0001558370-25-002637.md) | [15.1](/filings/0001558370-25-008463.md) | [16.8](/filings/0001558370-25-011952.md) | [20.5](/filings/0001104659-26-024970.md) | [21.7](/filings/0001104659-26-071183.md) | [24.4](/filings/0001104659-26-104501.md) | [48.2](/filings/0001104659-26-024970.md) | [54.2](/filings/0001104659-26-071183.md) | [70.4](/filings/0001104659-26-104501.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 79,954,196 at 2026-08-27, from the cover of the [10-Q filed 2026-09-02](/filings/0001104659-26-104501.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.